Dualitas Therapeutics

Company Overview

Dualitas Therapeutics is a private US biotech in South San Francisco building bispecific antibodies (BsAbs) for immunology and inflammation (I&I). Its distinguishing idea is the proximity engager: one arm binds a therapeutic target, the other pulls a second cell-surface protein into close contact, producing an effect neither arm delivers alone. Most bispecifics bolt two inhibitors together and hope for an additive gain. A year after leaving stealth, Dualitas has a Roche partnership worth up to $1 billion and nothing in the clinic. Both are true at once, and together they are the story.

Headquarters and Global Presence

Dualitas runs from a single site in South San Francisco, in the cluster where its investors and most of its scientific talent already sit. For a company whose product is a screening engine rather than a manufacturing footprint, there is little reason to be anywhere else.

Founding and History

Founded in 2023 by antibody engineers and drug developers, Dualitas ran in stealth for two years before emerging on 16 September 2025 with a $65 million Series A. Two years of quiet work before a single public word is unusual, and it showed in how finished the science looked on launch day.

Therapy Areas and Focus

Dualitas works only in immunology and inflammation, and inside that it has chosen crowded, well-validated indications rather than rare ones. DTX-102 is aimed at rheumatoid arthritis, DTX-101 at dermatologic and gastrointestinal autoimmune disease, and DTX-103 at allergic disease. These are markets with approved drugs and settled standards of care, which raises the bar rather than lowering it: a new bispecific has to beat something that already works, not simply exist where nothing does. The company's answer is that its molecules are not new targets but better pharmacology against proven ones.

Technology Platforms and Modalities

Two technologies sit under the pipeline. The proximity engager is the therapeutic idea, pairing an engager arm with a targeting arm to force cell-surface proteins together, producing activity a monospecific antibody cannot reach. DualScreen is how candidates are found: rather than testing pre-chosen pairs it screens the cell surfaceome, arraying up to 100,000 combinations in functional assays to find pairs that are synergistic rather than additive. That is commercial as well as scientific: a company screening at that scale has something to license long before its own molecules produce data.

Key Pipeline and Programs

DTX-102 is the lead development candidate. It pairs an optimized anti-CD28 arm with an immune proximity engager and is aimed at rheumatoid arthritis. Dualitas reports that in preclinical studies it was substantially more potent than a commercially approved comparator, with better dosing potential. IND-enabling studies are under way and the company expects it to enter the clinic in 2027. No Dualitas candidate has yet reached Phase I.

DTX-101 pairs an anti-IL-2R-beta arm with an engager arm, with first indications in dermatologic and gastrointestinal autoimmune disease.

DTX-103 pairs an anti-FceR1 arm with an engager arm for allergic disease. Its mechanism does not depend on circulating IgE levels, which the company argues avoids the slow onset and patient restrictions that limit current anti-IgE therapy.

Note what moved. At the September 2025 launch DTX-103 was named first and allergy looked like the opening play. By June 2026 the lead was DTX-102 and the opening indication was rheumatoid arthritis. Reordering a pipeline nine months out of stealth is not unusual, but it means the first clinical readout will land in a large, competitive indication rather than a cleaner one.

Recent Developments

In June 2026 Karim Dabbagh joined as chief executive, with Rich Murray, the interim chief executive, remaining on the board. The same announcement nominated DTX-102 as lead development candidate and disclosed two further preclinical programs across allergy, dermatology and gastrointestinal disease.

On 17 September 2026 came the Roche (SIX: ROG) deal: $36.5 million upfront, milestones, tiered royalties and a headline value of up to $1 billion. Dualitas will screen more than 300,000 bispecific combinations, and Roche takes everything afterward, from preclinical development to commercialization.

Key Personnel

Karim Dabbagh became chief executive in June 2026, from Silver Creek Pharmaceuticals and before that Second Genome. He earlier ran Pfizer's immunoregulation department and held leadership roles in inflammation discovery at Roche, worth noting given who signed in September.

Greg Lazar, co-founder and chief scientific officer, led research groups at Genentech, Eli Lilly and Xencor. Forbes Huang, co-founder and chief operating officer, came through Gyroscope Therapeutics and IVERIC bio.

Strategic Partnerships

The Roche collaboration is the only disclosed partnership and the one that matters. Roche takes the output of DualScreen in immunology and inflammation; Dualitas keeps DTX-102 and its internal programs. The structure says what Dualitas thinks it is selling: the engine, not the molecules.

FAQ Section